Five Weeks on a Artificial Lung: Child with Leukemia Survives Severe Respiratory Failure

A five-year-old boy undergoing treatment for the most common childhood cancer has survived one of the most feared complications in pediatric intensive care, thanks to an extraordinary 34-day run on an extracorporeal life-support machine. In a case report published in the Journal of Artificial Organs, a team of Turkish physicians describes how prolonged venovenous extracorporeal membrane oxygenation, or VV-ECMO, kept the child alive through severe pediatric acute respiratory distress syndrome, a condition in which the lungs become so inflamed and flooded that conventional ventilators can no longer deliver enough oxygen to the blood. The boy, who had been diagnosed with low-risk B-cell acute lymphoblastic leukemia, was eventually weaned from the circuit, discharged after 235 days in hospital, and, according to the report, recovered from the episode.

The case matters because it pushes against a long-standing boundary in critical care. Children with active malignancy have traditionally been considered poor candidates for ECMO, the technology that drains blood from the body, passes it through an artificial membrane lung where it picks up oxygen and releases carbon dioxide, and returns it warmed to the circulation. Historical series reported high mortality in cancer patients placed on the machine, and many centers treated a leukemia diagnosis as a relative contraindication. The new report, led by Hasan Özen of Selçuk University Faculty of Medicine in Konya with colleagues from Ankara University, Antalya Training and Research Hospital, Ondokuz Mayıs University and Mamak State Hospital, adds to a small but growing body of evidence that carefully selected oncology patients can benefit when the underlying lung injury is potentially reversible and the cancer itself carries a favorable prognosis.

To understand why this case is notable, it helps to unpack the two conditions that collided in this child. Acute lymphoblastic leukemia is a cancer of the blood-forming tissue in which immature lymphoid cells proliferate uncontrollably in the bone marrow. It accounts for roughly three-quarters of childhood leukemias, and modern multi-agent chemotherapy cures the great majority of children, particularly those classified as low-risk, as this boy was. Induction therapy, the intensive first phase of treatment, aims to clear leukemic blasts from the marrow and blood, but it also ravages normal immune cells, leaving patients profoundly immunosuppressed and vulnerable to opportunistic infections and inflammatory lung injury during the very weeks when their marrow is least able to fight back.

Pediatric acute respiratory distress syndrome, or PARDS, is the other half of the equation. It is the childhood counterpart of the adult syndrome first described in 1967 as acute respiratory distress in adults: a catastrophic inflammatory response in which the delicate alveolar membrane that performs gas exchange breaks down, floods with protein-rich fluid, and collapses. In children, PARDS remains a significant cause of death in intensive care units worldwide. Treatment is fundamentally supportive, relying on mechanical ventilation with careful pressure and volume settings, and, in the most severe cases, on rescue therapies such as prone positioning, inhaled pulmonary vasodilators, and ultimately ECMO. When hypoxemia becomes refractory, meaning the blood cannot be oxygenated even with optimized ventilator settings, ECMO is the last resort: it takes over the gas-exchange function of the lungs entirely while the injured organ is given time to heal.

Venovenous ECMO, the configuration used in this child, is the preferred mode for pure respiratory failure. Unlike venoarterial ECMO, which drains venous blood and returns oxygenated blood to the arterial system to support both lungs and heart, VV-ECMO returns the oxygenated blood to a vein, relying on the patient’s own heart to pump it through the body. It requires less invasive cannulation, avoids arterial complications, and carries a lower burden of circuit-related events, which is why pediatric centers increasingly favor it when cardiac function is intact. The trade-off is that the patient’s own circulation must be robust enough to distribute the oxygenated blood, a condition this boy met despite the severity of his lung disease.

What distinguishes this report is duration. Thirty-four days on VV-ECMO is a long run by any standard, and prolonged support multiplies the technical challenges. Circuits are prone to clotting, requiring continuous anticoagulation that must be balanced against bleeding risk, a particularly delicate calculation in a child with leukemia whose platelet counts and clotting factors fluctuate with his disease and chemotherapy. Infection risk rises with every day of cannulation, a serious concern in an immunosuppressed host. Prior case literature includes reports such as a child with leukemia supported on prolonged VV-ECMO despite persistent bacteremia, illustrating both the feasibility and the hazards of extended support in this population. That this boy’s circuit ran for more than a month and was ultimately decannulated successfully speaks to intensive multidisciplinary management spanning pediatric intensivists, hematologists, and perfusion specialists.

The broader context for oncology patients on ECMO has been shifting. Large database analyses, including studies drawing on the pediatric health information system, have examined mortality in high-risk populations and found that outcomes, while still worse than in the general pediatric ECMO population, are not uniformly dismal. The Extracorporeal Life Support Organization’s accumulated experience, reported by Gow and colleagues more than a decade ago, documented survival in children with malignancy supported for respiratory or cardiac failure, and the multicenter PEDECOR experience published in 2020 specifically evaluated outcomes in pediatric oncology patients and those following hematopoietic stem cell transplantation. The consistent message across these studies is that selection is everything: children whose respiratory failure is reversible and whose malignancy is controllable fare far better than those with progressive disease or refractory organ failure.

This case aligns squarely with that message. The boy’s leukemia was classified as low-risk, meaning his oncological outlook was favorable even before the respiratory catastrophe struck. His lung injury, though severe enough to require a month of artificial lung support, was ultimately reversible, and once his lungs recovered sufficiently, the team was able to remove the cannulas and continue his recovery on conventional care. The 235-day hospitalization underscores the long road such patients travel, encompassing not only the ECMO run but the completion of leukemia induction therapy, rehabilitation from prolonged critical illness, and management of the many complications that accumulate during months in intensive care. Yet the endpoint, discharge home, is the outcome that matters.

For the intensive care community, the report offers a data point in an evolving conversation about when to offer extracorporeal support to children with cancer. The authors suggest that prolonged VV-ECMO may be a feasible rescue strategy in carefully selected children with acute lymphoblastic leukemia when respiratory failure is potentially reversible and the oncological prognosis is favorable. That framing is deliberately cautious. It does not argue that every child with leukemia and lung failure should be placed on ECMO; it argues that the diagnosis alone should not be an automatic exclusion. As ECMO technology improves, with better circuits, refined anticoagulation monitoring, and growing institutional experience, the threshold for offering support to previously excluded groups continues to be re-examined, and single-case evidence like this contributes to that reassessment.

The case also highlights the human and systemic dimensions of such care. A 34-day ECMO run within a 235-day admission represents an enormous investment of intensive care resources and an extraordinary commitment by the child’s family, who provided written informed consent for the publication of his clinical details and imaging. Institutional ethics approval governed the report. For other centers weighing similar decisions, the takeaway is that outcomes in pediatric oncology ECMO are improving and that favorable leukemia risk categories, in particular, may justify accepting the risks of prolonged support. As the authors and the accumulating literature suggest, the question facing clinicians is no longer simply whether a child with cancer can be placed on ECMO, but whether that individual child’s lung injury is likely to heal and their cancer is likely to be cured, and in this five-year-old’s case, the answer to both was yes.

Subject of Research: Prolonged venovenous ECMO support for severe pediatric acute respiratory distress syndrome in a child with acute lymphoblastic leukemia

Article Title: Successful management of long-term venovenous ECMO for severe PARDS in a child with acute lymphoblastic leukemia

Article References: Successful management of long-term venovenous ECMO for severe PARDS in a child with acute lymphoblastic leukemia. (n.d.). https://doi.org/10.1007/s10047-026-01598-z

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01598-z

Keywords: ECMO, venovenous ECMO, pediatric acute respiratory distress syndrome, acute lymphoblastic leukemia, pediatric intensive care, respiratory failure, artificial lung, extracorporeal life support, childhood cancer, case report, critical care, leukemia treatment